9 completed, 3 recruiting, 1 not yet recruiting, 1 unknown. 14 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 14 | Completed 9, Recruiting 3, Not yet recruiting 1, Unknown 1 |
| Phase 3 | 1 | Not yet recruiting 1 |
Follow Mental Fatigue: new trials by email Literature Review of Mental Fatigue trials Research Report on Mental Fatigue
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sildenafil to Prevent and Reduce Cancer Related Cognitive Impairment Sildenafil - Cancer | Phase 2 / Phase 3 | Not yet recruiting | The University of Texas Medical Branch, Galveston | 30 | 2027-06-15 | 2026-05-11 |
| Evaluating the Safety and Efficacy of PNMR as Treatment for Long COVID Paragon Novel Metabolic Regulator (PNMR), Dietary and Lifestyle Recommendations - Long COVID | Phase 2 | Recruiting | ParagonClinicals Inc. | 82 | 2026-05-20 | 2026-06-04 |
| Effects of Hemp-Derived Cannabinoids on Menopause Symptoms Hemp-derived cannabinoids, Placebo - Menopause, Perimenopause | Phase 2 | Recruiting | Washington State University | 104 | 2026-02-11 | 2026-03-10 |
| PATH to Reducing Burnout Among Peers Who Deliver Overdose Prevention Services (R61 Phase Pilot) PATH (Peer Advanced Training for total Health) - Burnout, Compassion Satisfaction | Phase 2 | Completed | Chestnut Health Systems | 18 | 2026-01-12 | 2026-10-16 |
| Evaluating the Neuromodulatory Effect of Ketamine in Long COVID-19 Ketamine only - Long COVID | Phase 2 | Completed | University of Texas at Austin | 20 | 2025-06-05 | 2026-09-17 |
| NE3107 in Adults With Neurological Symptoms of Long COVID NE3107, Placebo - Long COVID | Phase 2 | Completed | BioVie Inc. | 203 | 2025-04-29 | 2026-09-22 |
| Impact of Cannabinoids on Menopause Symptoms Active Cannabinoid Product, Placebo - Perimenopause, Menopause | Phase 2 | Completed | Washington State University | 104 | 2025-03-03 | 2026-06-02 |
| Amantadine Therapy for Cognitive Impairment in Long COVID Amantadine - Long COVID, Post-COVID19 Condition | Phase 2 | Completed | Ohio State University | 64 | 2023-12-07 | 2026-01-27 |
| Randomized, Double-blind, Placebo-controlled Trial of the Efficacy and Safety of Tianeptine in the Treatment of Covid Fog Symptoms in Patients After COVID-19. Tianeptine, Placebo - Nervous System Diseases | Phase 2 | Recruiting | Military Institute od Medicine National Research Institute | 140 | 2023-02-17 | 2023-08-25 |
| Vortioxetine for Post-COVID-19 Condition Vortioxetine, Placebo - Post-COVID-19 Condition, Post-COVID-19 Syndrome | Phase 2 | Completed | Brain and Cognition Discovery Foundation | 149 | 2021-09-16 | 2025-01-16 |
| Examining the Effects of One-Month Probiotic Treatment on Mental Fatigue Probiotic formulation, Placebo - Mental Fatigue, Cognitive Function | Phase 2 | Completed | Swinburne University of Technology | 128 | 2018-08-30 | 2019-09-27 |
| Pharmaceutical Treatment of Fatigue After Aneurysmal Subarachnoid Hemorrhage OSU 6162, Placebo Oral Tablet - Aneurysmal Subarachnoid Hemorrhage | Phase 2 | Completed | Oslo University Hospital | 100 | 2017-09-05 | 2019-11-22 |
| Study Evaluating Efficacy and Safety of OSU6162 in the Treatment of Residual Symptoms After Stroke OSU 6162, Placebo oral tablet - Stroke Sequelae | Phase 2 | Completed | Arvid Carlsson Research AB | 101 | 2017-03-20 | 2020-10-01 |
| The Synergy Trial: Methylphenidate Plus a CFS-Specific Nutrient Formula as a Treatment for Chronic Fatigue Syndrome Methyl-P plus Nutrient Formula, Methyl-P plus Nutrient matched placebos - Chronic Fatigue Syndrome (CFS), Myalgic Encephalomyelitis (ME) | Phase 2 | Unknown | K-PAX Pharmaceuticals, Inc. | 134 | 2013-11-01 | 2014-09-25 |
Fatigue (5) · Post-Acute COVID-19 Syndrome (5) · COVID-19 (3) · Anxiety Disorders (2) · Pain (2) · Burnout, Psychological (1) · Cognition Disorders (1) · Cognitive Dysfunction (1) · Compassion Fatigue (1) · Confusion (1) · Fatigue Syndrome, Chronic (1) · Headache (1) · Memory Disorders (1) · Neoplasms (1)
Behavior (14) · Behavioral Symptoms (14) · Pathological Conditions, Signs and Symptoms (14) · Signs and Symptoms (14) · Fatigue (9) · Pathologic Processes (7) · Chronic Disease (6) · Coronaviridae Infections (6) · Coronavirus Infections (6) · Disease Attributes (6) · Infections (6) · Lung Diseases (6) · Nidovirales Infections (6) · Pneumonia (6) · Pneumonia, Viral (6)
OSU 6162 (2) · Amantadine (1) · Diet (1) · Methylphenidate (1) · Sildenafil Citrate (1) · Vortioxetine (1) · tianeptine (1)
Washington State University (2) · Arvid Carlsson Research AB (1) · BioVie Inc. (1) · Brain and Cognition Discovery Foundation (1) · Chestnut Health Systems (1) · K-PAX Pharmaceuticals, Inc. (1) · Military Institute od Medicine National Research Institute (1) · Ohio State University (1) · Oslo University Hospital (1) · ParagonClinicals Inc. (1) · Swinburne University of Technology (1) · The University of Texas Medical Branch, Galveston (1) · University of Texas at Austin (1)
United States (8) · Canada (2) · Australia (1) · Norway (1) · Poland (1) · Sweden (1)
Andrew B Scholey, PhD (1) · Andrew I Schamess, MD (1) · Angelika Sorteberg, MD (1) · Carl-Gerhard Gottfries, Prof. (1) · Dennis P Watson, PhD (1) · Jose Montoya, M.D. (1) · Melinda Sheffield-Moore, PhD (1) · Roger S. McIntyre, MD, FRCPC (1) · Sam Bock, BA Environmental Science (1) · W. Michael Brode, MD (1)
PMID 38114867, PMID 38424537, PMID 38520501, PMID 38860901, PMID 38954402, PMID 42498469
2016 (1)